Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSAEnriqueta Felip, S.-H. Lee, Shaolin Lü et al.|Annals of Oncology|2024Cited by 81
MA07.07 Validation Analysis of MET IHC as a Biomarker for Amivantamab-Lazertinib Response in Post-Osimertinib EGFR-Mutated NSCLCBenjamin Besse, E. Felip, P. Tomasini et al.|Journal of Thoracic Oncology|2025Cited by 1